Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | -$0.05 | -$0.04 | -$0.05 |
| Q2 2026 | 2 | -$0.05 | -$0.05 | -$0.05 |
| Q3 2026 | 1 | -$0.04 | -$0.04 | -$0.04 |
| Q4 2026 | 1 | -$0.05 | -$0.05 | -$0.05 |
| Q1 2027 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q2 2027 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q3 2027 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q4 2027 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q1 2028 | 1 | $0.02 | $0.02 | $0.02 |
| Q2 2028 | 1 | $0.02 | $0.02 | $0.02 |
| Q3 2028 | 1 | $0.02 | $0.02 | $0.02 |
| Q4 2028 | 1 | $0.02 | $0.02 | $0.02 |
Cytosorbents Corp last posted its earnings results on Wednesday, March 25th, 2026. The company reported $-0.09 earnings per share for the quarter, missing analysts' consensus estimates of $-0.05 by $0.04. The company had revenue of 8.86 M for the quarter and had revenue of 37.06 M for the year. Cytosorbents Corp has generated $0 earnings per share over the last year ($-0.13 diluted earnings per share) and currently has a price-to-earnings ratio of -3.02. Cytosorbents Corp has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/13/2026 | Q1 2026 | N/A | -$0.08 | N/A | $9.40 M | $8.86 M |
| 03/30/2026 | Q4 2025 | N/A | -$0.09 | N/A | $9.78 M | $9.23 M |
| 11/13/2025 | Q3 2025 | -$0.06 | -$0.05 | 0.01 | $10.40 M | $9.49 M |
| 08/07/2025 | Q2 2025 | -$0.07 | $0.03 | 0.1 | $9.40 M | $9.62 M |
| 05/14/2025 | Q1 2025 | -$0.08 | -$0.02 | 0.06 | $9.21 M | $8.73 M |
| 03/31/2025 | Q4 2024 | -$0.07 | -$0.14 | -0.07 | $10.25 M | $9.15 M |
| 11/07/2024 | Q3 2024 | -$0.07 | -$0.04 | 0.03 | $10.36 M | $8.61 M |
| 08/13/2024 | Q2 2024 | -$0.09 | -$0.08 | 0.01 | $9.68 M | $8.84 M |
| 05/09/2024 | Q1 2024 | -$0.12 | -$0.11 | 0.01 | $9.80 M | $8.99 M |
| 03/14/2024 | Q4 2023 | N/A | -$0.13 | N/A | N/A | $7.35 M |
| 11/09/2023 | Q3 2023 | -$0.12 | -$0.21 | -0.09 | N/A | $7.75 M |
| 08/01/2023 | Q2 2023 | -$0.11 | -$0.14 | -0.03 | N/A | $9.42 M |
| 05/02/2023 | Q1 2023 | -$0.13 | -$0.17 | -0.04 | N/A | $9.45 M |
| 03/09/2023 | Q4 2022 | -$0.17 | -$0.02 | 0.15 | N/A | $9.39 M |
| 11/03/2022 | Q3 2022 | -$0.16 | -$0.28 | -0.12 | N/A | $6.46 M |
| 08/02/2022 | Q2 2022 | -$0.14 | -$0.25 | -0.11 | N/A | $8.50 M |
| 05/03/2022 | Q1 2022 | -$0.15 | -$0.21 | -0.06 | N/A | $7.92 M |
| 03/10/2022 | Q4 2021 | N/A | -$0.22 | N/A | N/A | $10.78 M |
| 11/04/2021 | Q3 2021 | -$0.12 | -$0.15 | -0.03 | N/A | $8.90 M |
| 08/03/2021 | Q2 2021 | -$0.04 | -$0.11 | -0.07 | N/A | $11.37 M |
The conference call for Cytosorbents Corp's latest earnings report can be listened to online.
The conference call transcript for Cytosorbents Corp's latest earnings report can be read online.
Cytosorbents Corp (:CTSO) has a recorded annual revenue of $37.06 M.
Cytosorbents Corp (:CTSO) has a recorded net income of $-8,198,000.Cytosorbents Corp has generated $-0.13 earnings per share over the last four quarters.
Cytosorbents Corp (:CTSO) has a price-to-earnings ratio of -3.02 and price/earnings-to-growth ratio is 0.46.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED